These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8685072)

  • 1. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.
    Vandel S; Bertschy G; Baumann P; Bouquet S; Bonin B; Francois T; Sechter D; Bizouard P
    Pharmacol Res; 1995 Jun; 31(6):347-53. PubMed ID: 8685072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
    Conus P; Bondolfi G; Eap CB; Macciardi F; Baumann P
    Pharmacopsychiatry; 1996 May; 29(3):108-10. PubMed ID: 8738315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K
    Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.
    Harris MG; Benfield P
    Drugs Aging; 1995 Jan; 6(1):64-84. PubMed ID: 7696780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
    Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants.
    Souêtre E; Martin P; Lozet H; Monteban H
    Int Clin Psychopharmacol; 1996 Mar; 11(1):45-52. PubMed ID: 8732313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?
    Ashford JJ
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():27-31. PubMed ID: 7622820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tricyclic antidepressant plasma levels after fluoxetine addition.
    Vandel S; Bertschy G; Bonin B; Nezelof S; François TH; Vandel B; Sechter D; Bizouard P
    Neuropsychobiology; 1992; 25(4):202-7. PubMed ID: 1454161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Grapefruit juice as a contraindication? An approach in psychiatry].
    Vandel P; Regina W; Reix I; Vandel S; Sechter D; Bizouard P
    Encephale; 1999; 25(1):67-71. PubMed ID: 10205736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents].
    Bertschy G; Vandel S; Perault MC
    Therapie; 1994; 49(6):509-12. PubMed ID: 7878612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.
    Baumann P; Meyer JW; Amey M; Baettig D; Bryois C; Jonzier-Perey M; Koeb L; Monney C; Woggon B
    Ther Drug Monit; 1992 Feb; 14(1):1-8. PubMed ID: 1546384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
    Tulloch IF; Johnson AM
    J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased trimipramine plasma levels during fluvoxamine comedication.
    Seifritz E; Holsboer-Trachsler E; Hemmeter U; Eap CB; Baumann P
    Eur Neuropsychopharmacol; 1994 Mar; 4(1):15-20. PubMed ID: 8204992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine.
    Müller N; Brockmöller J; Roots I
    Ther Drug Monit; 1991 Nov; 13(6):533-6. PubMed ID: 1771652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies.
    Daniel WA; Syrek M; Haduch A; Wójcikowski J
    Exp Toxicol Pathol; 1999 Jul; 51(4-5):309-14. PubMed ID: 10445388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
    Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
    J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.